Comparison
Nicotinamide Riboside (NR) vs NMN
Nicotinamide Riboside (NR)
NAD+ precursor, the most-studied form for direct NAD+ elevation in humans. Branded as Niagen.
NMN
Nicotinamide mononucleotide, NAD+ precursor. Studied for cellular aging and metabolic health.
| Field | Nicotinamide Riboside (NR) | NMN |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 250–1000mg | 250–1000mg |
| Half-life | – | – |
| Onset | – | – |
| Evidence | EVIDENCEA | EVIDENCEB |
| Safety | ●●●●● | ●●●●● |
| Legal (US) | USOTC | USOTC |
| PubMed refs | 250 | 600 |
The comparison in plain English
Two NAD+ precursors marketed for longevity. NR (nicotinamide riboside) has the longer human RCT track record, Trammell 2016, Martens 2018, Dollerup 2018. NMN (nicotinamide mononucleotide) is one biosynthetic step closer to NAD+ and was the focus of the Sinclair lab's work.
Bottom line
Both raise NAD+ in human RCTs at ~40–90%. The downstream benefit evidence is suggestive but not definitive for either. NR has the larger evidence base; NMN has the marketing momentum. The price-per-dose is roughly equivalent.
Choose Nicotinamide Riboside (NR) if
You want the larger evidence base and the better-characterised dose-response curve. 250–1000mg AM.
Choose NMN if
You want the form one step closer to NAD+ and you find the Yoshino 2021 muscle-function evidence compelling. 250–1000mg AM.